| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Short Communication |






From the Vascular Biology*
and Transplant
Immunobiology
Groups, the John P.
Robarts Research Institute, and The University of Western
Ontario,
London, Canada; and the Department
of Surgery,
The Johns Hopkins University
School of Medicine, Baltimore, Maryland
| Abstract |
|---|
|
|
|---|
-actin by immunostain. Female-to-female
allografts in recipients with male bone marrow showed a limited number
of intimal Y-chromosome-positive cells. However, none of these
clearly co-labeled for smooth muscle
-actin and their numbers
declined throughout time, consistent with graft-infiltrating
inflammatory cells. We conclude that intimal expansion of mouse aortic
allografts is mediated by SMCs that originated from the recipient.
There was little evidence of their derivation from the bone
marrow, suggesting instead the adjacent host aorta as the
primary source of intimal SMCs.
| Introduction |
|---|
|
|
|---|
We have previously described a mouse aortic allograft model of chronic vascular rejection and used it to assess immunocellular responses.5 Allograft intimal thickening develops in this model within 3 to 4 weeks of grafting with the principal histological features of human allograft coronary disease, including an accumulation of intimal SMCs in a proteoglycan-rich matrix. We chose this model to investigate the origin of allograft intimal SMCs by analyzing different combinations of sex-mismatched mouse aortic allografts, using a Y-chromosome probe to distinguish cells of male lineage. We found a vast predominance of recipient-derived SMCs in the expanded allograft intima, with little evidence of their origin from the bone marrow, suggesting the adjacent recipient aorta as their primary source.
| Materials and Methods |
|---|
|
|
|---|
All mice were used in accordance with the guidelines of the Council on Animal Care of The University of Western Ontario, London, Canada. Male and female mice (age, 5 to 8 weeks; body weight, 25 to 30 g) of C57BL/6 (H-2b) and BALB/c (H-2d) strains (The Jackson Laboratory, Bar Harbor, ME) were used for aortic transplantation and bone marrow engraftment as specified.
Aortic Grafting and Experimental Design
Aortic segment transplantation was performed by end-to-end anastomosis in the infrarenal aorta as previously described.5 C57BL/6-to-BALB/c allografts were studied without immunosuppressive medication. Study groups included male-to-female allografts (n = 6); female-to-male allografts (n = 6); female-to-female allografts in recipients previously engrafted with male bone marrow (n = 10); and male-to-male or female-to-female allografts (sex-matched control; n = 2 each). The aortic graft, spleen, and testis/ovary were removed at 30 or 60 days after transplant as specified, fixed in 4% formaldehyde, embedded in paraffin, and sectioned 4-µm thick for standard histological staining, in situ hybridization, and immunohistochemical analysis. In addition, we performed sex-mismatched BALB/c-to-BALB/c aortic grafts (male-to-female; syngeneic control; n = 2) for standard histological assessment alone.
Bone Marrow Transfer
Female BALB/c mice were engrafted with male BALB/c bone marrow cells as described.6 Recipient mice were pretreated by total body irradiation at 650 Rad and then received 1 x 107 bone marrow cells in 0.3 ml of RPMI 1640 via tail vein injection within 6 hours of irradiation. No wasting or mortality was encountered in the reconstituted mice during 3 weeks of observation after irradiation. This was followed by aortic transplantation with the marrow-reconstituted mice serving as recipients. In situ hybridization for the Y chromosome was used to confirm male lineage repopulation of the recipient spleens sampled individually at the time of aortic graft retrieval.
In Situ Hybridization
The 145SC5 probe is a 1.5-kb cDNA fragment cloned into the EcoRI site of Bluescript vector and was obtained from Dr. Y. Nishioka (McGill University, Montreal, Canada).7 Digoxigenin-dUTP was incorporated by random primed labeling using a commercial kit (DIG-High Prime; Boehringer Mannheim, Laval, Quebec, CA). For in situ hybridization, tissue sections were dewaxed in xylene and endogenous peroxidase was quenched in 3% H2O2. The tissues were digested with 3 mg/ml pepsin in 0.1 N HCl for 6 minutes at 37°C, and then incubated for 20 minutes at 100°C with prehybridization buffer containing 50% deionized formamide, 5x standard saline citrate, 2% blocking reagent, 0.1% N-lauroylsarcosine, 0.02% sodium dodecyl sulfate, and 100 ng/ml salmon sperm DNA. Hybridization was performed at 37°C for 16 hours in hybridization buffer consisting of cDNA probe diluted 1:4 in prehybridization buffer. The slides were washed in a series of graded salt solutions (2x and 0.5x standard saline citrate twice each) and anti-digoxigenin sheep Fab conjugated with alkaline phosphatase (Boehringer Mannheim) was applied. A blue-black reaction was produced with nitroblue tetrazolium/bromochloroindolyl phosphate and nuclear fast-red was used as counterstain.
Immunostaining and Co-Labeling
A standard avidin-biotin immunoperoxidase technique8
was used with an Elite Vectastain kit (Vector Laboratories, Burlingame,
CA). Primary monoclonal antibodies were reactive to smooth muscle
-actin (clone 1A4; DAKO, Carpinteria, CA), CD3 (clone CD312;
Novocastra, Newcastle, UK) and Mac-3 (clone M3/84; PharMingen,
Mississauga, Ontario, CA). These were chosen for their demonstrated
effectiveness in formaldehyde-fixed mouse tissues. Negative controls
were performed by substituting nonimmune serum for primary antibody. In
the case of smooth muscle
-actin, isotype control IgG2a was also
used in place of clone 1A4. Diaminobenzidine was used as chromogen
(brown). To co-label by immunostain after in situ
hybridization, tissue sections were microwaved with 10 mmol/L sodium
citrate, pH 6.0, for 10 minutes for antigen retrieval. The sections
were immunostained for smooth muscle
-actin as above, except for
substituting the use of doubly dilute diaminobenzidine for color
development.
| Results |
|---|
|
|
|---|
In situ hybridization was performed on aortic allograft
sections using a digoxigenin-labeled cDNA probe for a repetitive
sequence in the mouse Y chromosome.7
This method produced
a positive signal over the cell nucleus in control sections of male
mouse spleen or testis (Figure 1A
,
inset), with absence of signal in female mouse spleen or ovary. In
male-to-female aortic allografts, no hybridization signal was detected
in the thickened intima, indicating a lack of donor-type cells in this
location (Figure 1A)
. Also, no hybridization signal was detected in the
media of these allografts. The latter finding is consistent with the
known inflammatory damage of the allograft media within the first 2
weeks of grafting in this model, with the consequent replacement of
medial SMCs by loose cellular debris and matrix.5
|
To evaluate this, we used co-labeling with in situ
hybridization for the Y chromosome followed by immunostaining for
cytoplasmic smooth muscle
-actin. The results of a representative
section of female-to-male aortic allograft before and after the
application of the second label are shown in Figure 1, C and D
,
respectively. Multiple intimal Y-chromosome-positive cells were
strongly immunoreactive for smooth muscle
-actin, substantiating
their identity as recipient-derived vascular SMCs. Conversely,
immunostaining for inflammatory cell subsets in subjacent sections
showed only a small minority of intimal cells to be positive for CD3 or
Mac-3 (T cells or macrophages, respectively, data not shown).
To address the novel possibility that allograft intimal SMCs may
develop from a precursor fraction of recipient bone marrow, we examined
aortic allografts from female C57BL/6 donors placed into female BALB/c
recipients engrafted previously with male BALB/c bone marrow cells. In
these mice, native bone marrow had first been ablated by total body
irradiation. The marrow-reconstituted mice thus preserved their inbred
BALB/c haplotype but were chimeric for having male lineage cells of
bone marrow origin. In situ hybridization for the Y
chromosome in spleen sections of these mice at aortic graft retrieval
(
2 months after reconstitution) demonstrated a robust repopulation
of the periarteriolar lymphoid sheath by male lineage cells (Figure 2A)
. Aortic allografts in these chimeric
recipients developed intimal thickening indistinguishable from that in
nonchimeric recipients. In situ hybridization for the Y
chromosome in the thickened allograft intima of these chimeric
recipients showed male lineage cells although in low abundance (Figure 2B)
. Moreover, the scattered Y-chromosome-positive cells present could
not be clearly identified as vascular SMCs by co-labeling and their
numbers diminished from 30 to 60 days after transplant, in keeping with
a subsiding inflammatory cell response. The co-labeling procedure did
highlight plentiful, singly positive, intimal cells expressing smooth
muscle
-actin. The data thus suggest that few, if any, of the
allograft intimal SMCs were derived from recipient bone marrow.
|
| Discussion |
|---|
|
|
|---|
A contribution of recipient SMCs to allograft intimal expansion has been suggested in the rat aortic allograft model. Inward migration of recipient SMCs was implicated by the pattern of intimal lesion formation after cryoablation of either the donor or the recipient side of the graft anastomosis.9 However, no marker was used in this study to distinguish donor from recipient cells. In a different study, fluorescence cell scanning of allograft intimal cell suspensions detected only the recipient serotype, although the extent to which SMCs were represented in suspension was unknown.10 In this study, as in a separate study in mice,11 immunostaining for major histocompatibility class II molecules failed to disclose the donor or recipient origin of allograft intimal SMCs because of inadequate antigen expression. Thus, our data uniquely provide direct in situ evidence of the recipient origin of allograft intimal SMCs, incorporating the use of co-labeling for simultaneous determination of cell origin and cell type.
Pertinent information in humans is limited to a few studies involving one to two patients each. Two cases of coronary disease in female-to-male human heart transplants have been studied by fluorescence in situ hybridization for the Y chromosome.12 Hybridization signals were found over inflammatory cells but not over coronary medial or intimal SMCs, suggesting the donor origin of the latter. In a different report on a single patient, polymerase chain reaction for three polymorphic gene loci was used to compare the genotype of cells in coronary atherectomy fragments of a transplanted heart with that of biopsied donor myocardium and that of recipient blood leukocytes.13 Cells of recipient origin contributed as much as 10% of the genetic material associated with the coronary lesion but the data did not allow recipient blood contamination at atherectomy to be distinguished from pathogenic involvement of recipient-type cells in coronary lesion formation. In humans, therefore, the limited amount of data precludes a firm conclusion.
Our findings did not provide support for the contention that allograft
intimal SMCs may be derived from recipient bone marrow. The Y
chromosome probe may underestimate the presence of male lineage cells
because of positioning of the nuclei partly or completely off the plane
of section, and therefore it is conceivable that a small number of
marrow-derived cells were missed. However, our data are clearly
contrary to any major contribution of such cells to the composition of
the mature intimal lesion. It is also theoretically possible that the
relevant SMC precursor population was selectively lost during marrow
transfer, however we note that progenitor cells are typically more
resistant than differentiated ones. Moreover, an aliquot of the marrow
transfer inoculum was placed in culture in medium enriched for vascular
SMC growth as we previously used.14
We observed in these
marrow cultures the emergence of cells with typical SMC morphology
replete with suitable immunoreactivity for markers such as smooth
muscle
-actin and calponin (data not shown). Therefore, in the final
analysis, we believe that marrow-derived SMCs are not materially
responsible for the expanded intima of mouse aortic allografts.
In summary, we have shown by in situ hybridization for the Y chromosome in sex-mismatched mouse aortic allografts that the expanded intima, which is characteristic of allograft vascular disease, is comprised of abundant vascular SMCs of recipient origin. These cells seem to have arisen from the adjacent portions of the recipient aorta, in contrast to a significant contribution from a recipient bone marrow source.
| Acknowledgements |
|---|
| Footnotes |
|---|
Supported by grant T3583 from the Ontario Heart and Stroke Foundation.
Accepted for publication March 1, 2001.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
Q. Xu Stem Cells and Transplant Arteriosclerosis Circ. Res., May 9, 2008; 102(9): 1011 - 1024. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F. Bentzon, C. S. Sondergaard, M. Kassem, and E. Falk Smooth Muscle Cells Healing Atherosclerotic Plaque Disruptions Are of Local, Not Blood, Origin in Apolipoprotein E Knockout Mice Circulation, October 30, 2007; 116(18): 2053 - 2061. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. N. Mitchell and P. Libby Vascular Remodeling in Transplant Vasculopathy Circ. Res., April 13, 2007; 100(7): 967 - 978. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Visconti, Y. Ebihara, A. C. LaRue, P. A. Fleming, T. C. McQuinn, M. Masuya, H. Minamiguchi, R. R. Markwald, M. Ogawa, and C. J. Drake An In Vivo Analysis of Hematopoietic Stem Cell Potential: Hematopoietic Origin of Cardiac Valve Interstitial Cells Circ. Res., March 17, 2006; 98(5): 690 - 696. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Religa, K. Bojakowski, M. Bojakowska, Z. Gaciong, J. Thyberg, and U. Hedin Allogenic immune response promotes the accumulation of host-derived smooth muscle cells in transplant arteriosclerosis Cardiovasc Res, February 1, 2005; 65(2): 535 - 545. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Xu Mouse Models of Arteriosclerosis: From Arterial Injuries to Vascular Grafts Am. J. Pathol., July 1, 2004; 165(1): 1 - 10. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. C. Cooley Murine Model of Neointimal Formation and Stenosis in Vein Grafts Arterioscler. Thromb. Vasc. Biol., July 1, 2004; 24(7): 1180 - 1185. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Zhang, N. J. Freedman, L. Brian, and K. Peppel Graft-Extrinsic Cells Predominate in Vein Graft Arterialization Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): 470 - 476. [Abstract] [Full Text] |
||||
![]() |
A. Luttun and P. Carmeliet De novo vasculogenesis in the heart Cardiovasc Res, May 1, 2003; 58(2): 378 - 389. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sata, K. Tanaka, R. Nagai, Y. Hu, H. Dietrich, F. Davison, M. Mayr, Q. Xu, B. Ludewig, M. Erdel, et al. Origin of Smooth Muscle Progenitor Cells: Different Conclusions From Different Models * Response Circulation, April 29, 2003; 107 (16): e106 - e107. [Full Text] [PDF] |
||||
![]() |
T. M. DOHERTY, P. K. SHAH, and T. B. RAJAVASHISTH Cellular origins of atherosclerosis: towards ontogenetic endgame? FASEB J, April 1, 2003; 17(6): 592 - 597. [Full Text] [PDF] |
||||
![]() |
J.-L. Hillebrands, F. A. Klatter, and J. Rozing Origin of Vascular Smooth Muscle Cells and the Role of Circulating Stem Cells in Transplant Arteriosclerosis Arterioscler. Thromb. Vasc. Biol., March 1, 2003; 23(3): 380 - 387. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hu, M. Mayr, B. Metzler, M. Erdel, F. Davison, and Q. Xu Both Donor and Recipient Origins of Smooth Muscle Cells in Vein Graft Atherosclerotic Lesions Circ. Res., October 4, 2002; 91 (7): e13 - e20. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Thyberg Re-endothelialization Via Bone Marrow-Derived Progenitor Cells: Still Another Target of Statins in Vascular Disease Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1509 - 1511. [Full Text] [PDF] |
||||
![]() |
Y. Hu, F. Davison, B. Ludewig, M. Erdel, M. Mayr, M. Url, H. Dietrich, and Q. Xu Smooth Muscle Cells in Transplant Atherosclerotic Lesions Are Originated From Recipients, but Not Bone Marrow Progenitor Cells Circulation, October 1, 2002; 106(14): 1834 - 1839. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Russell, C. M. Chase, M. Sykes, H. Ito, J. Shaffer, and R. B. Colvin Tolerance, Mixed Chimerism, and Chronic Transplant Arteriopathy J. Immunol., November 15, 2001; 167(10): 5731 - 5740. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |